Biocon’s arm gets European Commission’s nod for YESAFILI

20 Sep 2023 Evaluate

Biocon’s subsidiary -- Biocon Biologics has received marketing authorization from European Commission (EC) for YESAFILI, Biosimilar Aflibercept. The EC decision follows the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending approval of YESAFILI in July.

YESAFILI, an ophthalmology product, is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV). It is highly similar to the reference product Eylea (aflibercept). Data shows that YESAFILI has comparable quality, safety, and efficacy to Eylea.

The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway. Aflibercept had EU brand sales of approximately $1.8 billion for the 12 months ending December 31, 2022, according to IQVIA.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

338.35 -6.10 (-1.77%)
12-Jun-2024 11:34 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1507.80
Dr. Reddys Lab 6060.65
Cipla 1549.10
Zydus Lifesciences 1085.60
Lupin 1605.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.